Company Overview and News

 
Simavita bags $1.5M to advance incontinence sensor technology

2017-05-08 proactiveinvestors.com.au
Simavita (ASX:SVA) has raised $1.5 million from a share placement after receiving strong support from new and existing shareholders.
Upvote Downvote

 
Simavita secures $1.5m in funding

2017-05-08 marketwired
SYDNEY, AUSTRALIA--(Marketwired - May 8, 2017) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA) is pleased to announce that as a result of support from new investors and existing shareholders it had raised $1,500,000.
Upvote Downvote

 
Simavita Announces Up to A$2.93 Million Financing Program

2017-05-03 marketwired
SYDNEY, AUSTRALIA--(Marketwired - May 3, 2017) - Simavita Limited (Simavita or the Company) (ASX:SVA) today announced a financing program of up to A$2.93 million split between a Placement to institutional and sophisticated investors for A$1.5million together with a Non-Renounceable Rights Issue of 1 new CDI for 7 existing CDI's held by holders which may raise up to a further A$1.43 million.
Upvote Downvote

 
Simavita Releases ASX Appendix 4C for the Quarter Ended December 31, 2016

2017-01-30 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Jan. 30, 2017) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA) today reported its 31 December, 2016 quarter results together with financial highlights during the period.
Upvote Downvote

 
Simavita Receives $1.65 Million Cash Payment Under R&D Tax Incentive Scheme

2016-12-19 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Dec. 19, 2016) - Simavita Limited (ASX:SVA) ("Simavita" or the "Company") is pleased to confirm the receipt of $1,659,600 under the Australian Government's Research and Development Tax Incentive Scheme. The claim covers the year ended 30 June 2016.
Upvote Downvote

 
Simavita releases unaudited financial statements and MD&A for the three-month period ended September 30, 2016

2016-12-02 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Dec. 2, 2016) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA), is refiling its financial results in accordance with Canadian reporting requirements for the first quarter ended September 30, 2016.
Upvote Downvote

 
Simavita releases unaudited financial statements and MD&A for the three-month period ended September 30, 2016

2016-11-29 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Nov. 29, 2016) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA), today released its financial results in accordance with Canadian reporting requirements for the first quarter ended September 30, 2016.
Upvote Downvote

 
Simavita Limited: 2016 Annual General and Special Meeting Results

2016-11-28 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Nov. 28, 2016) - Simavita Limited (ASX:SVA) today is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 11:00 am today (Australian Eastern Daylight Time) in North Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of annual general and special meeting & information circular are attached.
Upvote Downvote

 
Simavita releases home care system - AssessPLUS(TM), an incontinence solution for NDIS and Home Care Package recipients

2016-11-15 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Nov. 15, 2016) - Simavita Limited (ASX:SVA) today announced the release of AssessPLUS™, the Company's new automated incontinence assessment solution for use by carers helping National Disability Insurance Scheme (NDIS) participants and seniors living in the community and receiving Home Care Packages. AssessPLUS™ is simultaneously being launched in Europe and North America.
Upvote Downvote

 
Simavita Releases Materials for 2016 Annual General and Special Meeting

2016-10-31 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Oct. 31, 2016) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA) is pleased to release the materials for its 2016 Annual General and Special Meeting (the "Meeting").
Upvote Downvote

 
Simavita releases progress update

2016-10-21 marketwired
SYDNEY, AUSTRALIA--(Marketwired - Oct. 20, 2016) - Simavita Limited ("Simavita" or the "Company") (ASX:SVA) today delivered a progress update to the market. In a few short months the Company has delivered significant change. We have:
Upvote Downvote

 
Simavita Releases ASX Appendix 4C for the Quarter Ended June 30, 2016

2016-07-28 marketwired
SYDNEY, AUSTRALIA--(Marketwired - July 28, 2016) - Simavita Limited (ASX:SVA) (TSX VENTURE:SV) ("Simavita" or the "Company"), a global leader in the digital healthcare sector, is pleased to release its ASX Appendix 4C for the quarter ended June 30, 2016.
Upvote Downvote

 
Simavita Limited Voluntarily Delists From the Canadian TSX Venture Exchange

2016-07-25 marketwired
SYDNEY, AUSTRALIA--(Marketwired - July 25, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) advises that it has received notice from the TSX Venture Exchange (the "TSX-V") that the Company's securities will be delisted from the TSX-V effective at the close of business on August 3, 2016 and therefore will no longer be traded on the TSX-V after that date.
Upvote Downvote

 
Simavita Limited: Appointment of Company Secretary

2016-07-13 marketwired
SYDNEY, AUSTRALIA--(Marketwired - July 13, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) advises the appointment of Nathan Bartrop as Joint Company Secretary.
Upvote Downvote

 
Simavita Secures $7.3m in Funding

2016-06-29 marketwired
SYDNEY, AUSTRALIA--(Marketwired - June 29, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) is pleased to announce that as a result of significant support from its shareholders it had raised $7,353,000.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...